Markets:

Overview

News

Currencies

International

Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

1.638 +0.048 (+3.04%)

Streaming Delayed Price Updated: 12:28 PM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗

August 28, 2025

Via Benzinga

Why Is CEL-SCI Stock Crashing After-Hours? ↗

August 28, 2025

CEL-SCI's shares dropped 38.19% after announcing a $10 million public offering priced below market value to fund its cancer immunotherapy development.

Via Benzinga

CEL-SCI Announces Pricing of $10 Million Public Offering

August 27, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Proposed Public Offering

August 27, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

August 14, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

August 13, 2025

From CEL-SCI Corporation

Via Business Wire

Which stocks are experiencing notable movement on Wednesday? ↗

July 30, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 30, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

July 30, 2025

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

July 14, 2025

From CEL-SCI Corporation

Via Business Wire

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 14, 2025

Via Benzinga

Why Datavault AI Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗

July 14, 2025

Via Benzinga

Topics Artificial Intelligence

Which stocks are moving on Friday? ↗

July 11, 2025

Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled ↗

July 11, 2025

The formal agreement is expected to be signed with the Saudi pharmaceutical partner in the coming weeks, CEL-SCI said.

Via Stocktwits

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

July 11, 2025

From CEL-SCI Corporation

Via Business Wire

There are notable gap-ups and gap-downs in today's session. ↗

July 11, 2025

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

July 11, 2025

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Closing of Public Offering

May 23, 2025

From CEL-SCI Corporation

Via Business Wire

Keep an eye on the top gainers and losers in Thursday's session. ↗

May 22, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

June 18, 2025

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 22, 2025

Via Benzinga

These stocks are moving in today's session ↗

May 22, 2025

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Via Chartmill

Dow Moves Higher; US Initial Jobless Claims Fall ↗

May 22, 2025

Via Benzinga

Topics Stocks

Which stocks are gapping on Thursday? ↗

May 22, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Nasdaq Gains Over 100 Points; BJ's Wholesale Earnings Top Views ↗

May 22, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 22, 2025

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 22, 2025

Via Benzinga

Why Urban Outfitters Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗

May 22, 2025

Via Benzinga

CEL-SCI Announces Pricing of Public Offering

May 21, 2025

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 21, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Cel-Sci Corporation Common Stock (NY:CVM)

All News about Cel-Sci Corporation Common Stock

Starting at /week.